Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab effects on eczema and skin barrier in atopic dermatitis
2024-519811-32-00Phase 4Authorised
- Sponsor
- Region Östergötland
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Region Östergötland. Primary endpoint: EASI-75 response at Week 24. Planned start Feb 2026; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-519811-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519811-32-00.